Tesamorelin 5mg

Tesamorelin 5mg — Modified GHRH Analog

Tesamorelin takes a fundamentally different approach to GHRH stabilization than CJC-1295. Instead of swapping amino acids to resist DPP-IV, it caps the N-terminus with a lipophilic trans-3-hexenoic acid group that blocks aminopeptidase access. And instead of truncating to 29 amino acids, it keeps all 44 — the full native GHRH sequence with protection bolted on.

Specifications

Three ways to stabilize GHRH

Sermorelin: no modifications, short half-life (~11 min), clean pulsatile release. CJC-1295 No DAC: four amino acid substitutions, moderate half-life (30 min-2 hours). Tesamorelin: full-length sequence with lipophilic N-terminal cap. Three different engineering philosophies applied to the same receptor target. Peptide Bio Sciences LTD stocks all three.

Research context

Protease assays have confirmed that the trans-3-hexenoic acid group provides effective aminopeptidase resistance. Published studies have examined Tesamorelin in pituitary GHRH receptor signaling, somatotroph response kinetics, and head-to-head comparisons with Sermorelin and CJC-1295.

Tesamorelin 5mg is Frequently paired with

• Ipamorelin 5mg — Available as Ipa/Tesa Blend.

Quality and testing

Third-party tested. Batch-specific COAs available.

Storage

• Lyophilized: -20°C
• Reconstituted: 2-8°C, use within 30 days

For laboratory research use only. Not for human or veterinary use.